CHAPTER 11

REFERENCES
References:


46. Delasko J, Cocchetto D, Burke L., Target product profile beginning drug development with the end in mind 2005, 1.


68. www.drugbank.com


70. http://www.pdr.net


78. Kappelhoff BS, pharmacokinetics, efficacy and safety of Nevirapine. Content developer: Maria Zolfo, MD, November '08.
79. Sreeraj M., Chan-Loi Yong, Todd D, Mark S. D., Thomas R. M., Mark C, Steven L. K.,
Deposition. 2009, 3(9).
Patrick R., Single Dose Pharmacokinetics and Bioavailability of Nevirapine in Healthy
81. Nevirapine. Clarke’s analysis of drug and poisons pharmaceutical press
84. Nevirapine. Martindel the complete drug reference.
85. Naseem A. C., Areeg A.A., Shamsher, A.S., Zidan Z. R., Quality by design approach
86. Jun H., Goldi K., Chunsheng C., Ramaro C., Pedro Hernandez- Abad, Krishnendu G.,
Arwinder N., Quality by design case study: An integrated multivariate approach to drug
32.
87. Ales B., Igor S., Damjana Z. B., Franc V., Tableting process optimisation with the
88. Mattias A., Anders R., Christina G., Multivariate methods in tablet formulation suitable
for early drug development: Predictive models from a screening design of several linked
responses, Chemometrics and Intelligent Laboratory Systems, , May 2007, 87(1):P.
125-130.